You are here

Home » Content

Diabetes Mellitus'lu Hastalarda Hepatit B ve Hepatit C Seroprevalansı

THE SEROPREVALANCE OF HEPATITIS B AND HEPATITIS C INFECTION IN PATIENTS WITH DIABETES MELLITUS

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2002

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
In this study, we investigated the relationship between diabetes mellitus and hepatitis B and hepatitis C infections. We used a sample of 179 patients diagnosed with type I and type 11 diabetes mellitus, together with a control group of 414 he¬althy donors. All cases were tested for HBsAg, anti-HBc(total), anti-HBs and anti-HCV antibodies. In addition, the patients were asked for liver function tests and predisposing factors. The factors investigated were (i) time since the diagnosis of diabe¬tes mellitus, (ii) drugs used for regulation, (iii) whether insulin had been used and for how long, and (iv) histories for alcohol intake, transfusions, blood and blood products transfusions, operations, accidents and jaundice. We found that 75 of 179 patients (41.9%) had been exposed to the hepatitis B virus and 6 (3.3%) patients had anti-HCV seropositivity. There were 12 (6.7%) HBsAg (+), 59 (32.9%) both anti-HBs and anti-HBc(total) (+), 4 (2.2%) only anti-HBc (total) (+) patients. We did not find a statistically significant relationship between the predisposing factors and seropositivity. Examination of liver function tests showed that 1% of the seropositive patients displayed high transaminase values. We observed that the ra¬tio of being exposed to hepatitis C was higher than hepatitis B in diabetic patients. There is no clinical evidence or epidemi-ological factor to explain this observation.
Bookmark/Search this post with
Abstract (Original Language): 
Bu çalışmada diabetes mellitus hastalığı ile B ve C hepatitleri-nin ilişkisini araştırmak için tip I ve tip II diabetes mellitus tanısı ile takip edilen 179 hasta incelendi. Kontrol grubu olarak 414 sağlıklı donör alındı. Bütün vakalarda HbsAg, anti-HBc(to-tal), anti-HBs ve anti-HCV antikorlarının yanı sıra hasta grubunda karaciğer fonksiyon testleri ile predispozan faktörler (diyabet tanısından sonra geçen süre, kan şekeri regülasyonu için kullandığı ilaç, insülin kullanıp kullanmadığı ve süresi ile alkol, kan ve kan ürünleri transfüzyonu, cerrahi operasyon, trafik ka¬zası ve geçirilmiş sarılık anamnezi) de araştırıldı. 179 hastanın 75'inin (%41.9) hepatit B virüsü ile karşılaştığı 12'sinin (%6.7) HBsAg (+) hasta, 59'unun (%32.9) hem anti-HBs, hem anti-HBc(total) (+) hasta, 4'ünün (%2.2) sadece anti-HBc(total) (+) olduğu) saptanırken, 6'sında (%3.3) anti-HCV seropozitifliği saptandı. Seropozitivite ile predispozan faktörler arasında anlamlı bir ilişki saptanmadı. Seropozitif hastaların %1'inde tran-saminaz yüksekliği görüldü. Diabetes mellituslu hastalarda hepatit C ile karşılaşma oranının hepatit B'ye göre daha fazla olduğu gözlendi. Bunun nedenini açıklayabilecek epidemiyolojik faktör veya klinik bulgu tespit edilemedi.
FULL TEXT (PDF): 
PDF icon arastrmx_116859_6_pp_105-109.pdf
  • 3
105-109
  • Turkish

REFERENCES

References: 

1. Fıçıcıoğlu C, Mikla S, Midilli K ve ark. Reduced immune response to hepatitis B vaccine in children with insulin-dependent diabetes. Acta Pa-ediatr Jpn 1995; 37(6): 687-90.
2. Helcl J. Diabetes and viral hepatitis B. Cesk Epidemiol Mikrobiol Imunol 1992; 41(3): 166-8.
3. Özyılkan E, Arslan M. Increased prevalance of diabetes mellitus in patients with chronic hepatitis C virus infection (letter). Am J Gastroenterol 1996; 91: 1480-1.
4. Grimbert S, Valensi P, Levy-Marchal C ve ark. High prevalance of diabetes mellitus in patients with chronic hepatitis C. A case-control study. Gastroenterol Clin Biol 1996; 20(6-7): 544-8.
5. Simo R, Hernandez C, Genesca J ve ark. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care 1996; 19(9): 998¬1000.
6. Kurt H,
Ilgı
n fi, Çorapçıoğlu D ve ark. Diabetes mellitus'ta hepatit C virüs enfeksiyonu prevalansı. Türk Diabet Yıllığı 1997-1998;13: 12-6.
7.
Taşyara
n M. Hepatit B epidemiolojisi. Viral Hepatit 98'de. Ed. Kılıçtur-gay K. 1. baskı. istanbul, 1998; 94-100.
8.
Akkı
z H. HCV enfeksiyonu epidemiolojisi. Viral Hepatit 98'de. Ed. Kı-lıçturgay K. 1. baskı.Istanbul,1998; 148-61.
9. Chisari FV, Ferari C. Hepatitis B virus immunopathogenesis. Annu Rev
Immunol 1995; 13: 29-60.
10. Williamson
JR
, Tilton RG, Chang K, Kilo C. Basement membrane ab¬normalities in diabetes mellitus: relationship to clinical microangiopathy.
Diabetes Metab Rev 1988; 4: 339-70.
11. Mowat AG, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med 1971; 284: 621-7.
12. Molenaar DM, Palumbo PJ, Wilson WR, Ritts RE Jr. Leukocyte che-motaxis in diabetic patients and their nondiabetic first-degree relatives.
Diabetes 1976; 25: 880-3.
13. Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function in pati¬ents with poorly controlled diabetes. Diabetes 1974; 23: 9-15.
14. Tan JS, Anderson JL, Watanakunakorn C, Phair JP. Neutrophil dysfunction in diabetes mellitus. J Clin Lab Med 1975; 85: 26-33.
108 | O r b a y E v e ark. | D i a b e t e s M e l l i t u s ' l u H a s t a l a r d a H e p a t i t B v e H e p a t i t C Seroprevalansı
15. Andersen B, goldsmith GH, Spagnuolo PJ. Neutrophil adhesive dysfunction in diabetes mellitus: the role of cellular plasma factors. J Lab
Clin Med1980; 111: 275-85.
16. Sentochnik D, Eliopoulos G. Infection and diabetes. Joslin's Diabetes Mellitus'ta. Ed. Kahn CR, Weir GC. 13. baskı. Leo and Febiger, Phila¬delphia 1994; 867-89.
17. Wismans PJ, van Hattum J, de Gast GC ve ark. A prospective study of invitro anti-HBs producing B cells (spot ELISA) following primary and supplementary vaccination with a recombinant hepatitis B vaccine in in¬sulin-dependent diabetic patients and matched controls. Journal of Medical Virology 1991; 35: 216-22.
18. Douvin C, Simon D, Charles MA ve ark. Hepatitis B vaccination in di¬abetic patients. Randomized trial comparing recombinant vaccines con¬taining and not containing pre-S2 antigen. Diabetes Care 1997; 20(2):
148-51.
19. Gray H, Wreighitt T, Stratton IM ve ark. High prevalence of hepatitis C infection in Afro-Caribbean patients with type 2 diabetes and abnormal
liver function tests. Diabet Med 1995; 12(3): 244-9.
20. Özyılkan E, Erbas T, Şimşek H ve ark. Increased prevalence of hepati¬tis C virus antibodies in patients with diabetes mellitus. Journal of Inter¬nal Medicine 1994; 235(3): 283-4.

Thank you for copying data from http://www.arastirmax.com